Clinical Trial Activity for Small-Cell Lung Cancer Increases but Remains Dominated by Small Phase 2 Studies
A cross-sectional registry analysis shows a marked rise in trials initiated after 2016 and a significant increase in industry sponsorship.
Key takeaways
- Small-cell lung cancer clinical trial registrations increased markedly after 2016, with 63.3% of trials in a 30-year database initiated between 2016 and 2025.
- Although non-industry funding was the most common overall, industry-sponsored SCLC trials rose significantly from 10.3% in 1996-2000 to 37.8% in 2021-2025.
- The SCLC trial portfolio remains dominated by phase 2 studies, which represent 55.7% of all interventional trials registered.
- Nearly half of the registered trials (48.4%) enrolled fewer than 50 participants, and 91.5% were designed as open-label studies.
Small-cell lung cancer (SCLC) clinical trial activity has expanded substantially over the past decade, according to a cross-sectional study analyzing ClinicalTrials.gov registry records. The analysis, which characterized temporal changes in registry records over a 30-year period from 1996 to 2025, shows a marked increase in trials initiated after 2016. This growth has occurred alongside therapeutic developments in SCLC, including the incorporation of programmed death-ligand 1 (PD-L1) inhibitors into first-line treatment for extensive-stage disease and the emergence of novel therapies for relapsed SCLC.
Published in the Journal of Thoracic Disease in August 2026, the study evaluated 825 interventional SCLC trials registered with start dates between January 1, 1996, and December 31, 2025. Two oncologists independently screened eligible registry records, with a third reviewer resolving any disagreements, to compile data on trial phases, enrollment sizes, masking, allocation, funding, geographic participation, and recruitment status.
While the volume of SCLC research registrations has grown, the underlying trial characteristics show that early- and mid-phase, open-label designs with small participant groups continue to dominate the field. These design features are critical as the oncology community evaluates how the clinical research portfolio is structured to generate robust, confirmatory evidence.
What Happened
The study evaluated 825 interventional SCLC trials and found that the vast majority (97.7%) evaluated therapeutic interventions. More than half of the trials (55.7%) were phase 2 studies, and nearly half (48.4%) enrolled fewer than 50 participants. Additionally, 91.5% of the trials were open-label, meaning participants and researchers knew which treatment was being administered. Among the trials that reported allocation, 69.0% were randomized.
Trial activity was heavily concentrated in the United States and China. The volume of registered trials overall increased markedly after 2016, with 63.3% of all trials in the 30-year dataset initiated between 2016 and 2025.
While non-industry funding remained the most common source of support overall across the 30-year period, the proportion of industry-sponsored trials grew significantly. Industry sponsorship rose from 10.3% of trials during 1996-2000 to 37.8% of trials during 2021-2025 (trend P<0.0001).
What The Evidence Shows
The researchers conducted a cross-sectional analysis of ClinicalTrials.gov registry records. They identified interventional trials with start dates between January 1, 1996, and December 31, 2025, using the condition terms "Small-Cell Lung Cancer" or "SCLC." Categorical variables were summarized descriptively and compared across six five-year intervals using Pearson's chi-squared or Fisher's exact tests. The Cochran-Armitage trend test was utilized to evaluate the historical trajectory of industry sponsorship.
What We Don't Know Yet
The published study is a cross-sectional analysis of registry data and does not assess the final clinical results or treatment outcomes of the registered trials. The published source does not report other specific limitations.
What Comes Next
The study highlights the need for larger, internationally collaborative, confirmatory trials and more robust evidence generation to translate emerging therapeutic advances into improved outcomes for patients with SCLC. The published source does not report specific future plans or planned next steps by the investigators.
What This Means
The analysis shows that while clinical trial registrations have surged, the structural characteristics of the SCLC trial portfolio are still dominated by early- and mid-phase, open-label studies with relatively small participant cohorts. This suggests that while research interest is high, there is a need to transition from small-scale, early-phase studies into larger-scale research designs to generate robust, confirmatory evidence.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42724306/
Questions readers ask
- How has funding for small-cell lung cancer trials changed?
- While non-industry funding remains the most common source of support overall, industry sponsorship has increased significantly. It grew from 10.3% of registered trials in 1996-2000 to 37.8% of trials in 2021-2025.
- What are the most common designs for small-cell lung cancer trials?
- The SCLC trial portfolio is dominated by early- and mid-phase, open-label designs. Phase 2 trials represent 55.7% of all registered studies, 91.5% are open-label, and 48.4% enroll fewer than 50 participants.
- Where is small-cell lung cancer clinical trial activity concentrated?
- Clinical trial activity is concentrated in the United States and China. Overall SCLC trial registrations increased markedly after 2016.
What this means
The analysis shows that while clinical trial registrations have surged, the structural characteristics of the SCLC trial portfolio are still dominated by early- and mid-phase, open-label studies with relatively small participant cohorts. This suggests that while research interest is high, there is a need to transition from small-scale, early-phase studies into larger-scale research designs to generate robust, confirmatory evidence.
Limitations and uncertainties
- The published study is a cross-sectional analysis of registry data and does not assess the final clinical results or treatment outcomes of the registered trials. The published source does not report other specific limitations.
